Septic Shock Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) June 16, 2015 -- The report “Septic Shock - Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Septic Shock. Septic shock is life-threatening low blood pressure (shock) due to sepsis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Septic Shock with 30 market data tables and 14 figures, spread across 77 pages is available at http://www.rnrmarketresearch.com/septic-shock-pipeline-review-h1-2015-market-report.html .
Companies discussed in this Septic Shock - Pipeline Review, H1 2015 report include Adrenomed AG, Compugen Ltd., Ferring International Center S.A., Huons Co., Ltd., InflaRx GmbH, Lixte Biotechnology Holdings, Inc., Noxxon Pharma AG, Orion Oyj, Pharmazz, Inc., Spider Biotech, Takeda Pharmaceutical Company Limited, XImmune AB.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are adrecizumab, AM-12, BC-1215, BTZO-2, centhaquine, CGEN-25068, HBN-1, HBN-3, HBN-4, HU-003, IFX-1, LB-100, LB-102, LB-1148, levosimendan, MFH-147, NOXD-20, Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock, R-190, SB-056, selepressin, Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock, SP-14, SP-9, Synthetic Peptides for Inflammation and Infectious Disorders.
Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=390965 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report includes: Feb 02, 2015: Leading BioSciences Receives FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock; Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock.
List of Tables
Number of Products under Development for Septic Shock, H1 2015 10
Number of Products under Development for Septic Shock - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Septic Shock - Pipeline by Adrenomed AG, H1 2015 20
Septic Shock - Pipeline by Compugen Ltd., H1 2015 21
Septic Shock - Pipeline by Ferring International Center S.A., H1 2015 22
Septic Shock - Pipeline by Huons Co., Ltd., H1 2015 23
Septic Shock - Pipeline by InflaRx GmbH, H1 2015 24
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 25
Septic Shock - Pipeline by Noxxon Pharma AG, H1 2015 26
Septic Shock - Pipeline by Orion Oyj, H1 2015 27
Septic Shock - Pipeline by Pharmazz, Inc., H1 2015 28
Septic Shock - Pipeline by Spider Biotech, H1 2015 29
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 30
Septic Shock - Pipeline by XImmune AB, H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Septic Shock Therapeutics - Recent Pipeline Updates, H1 2015 69
Septic Shock - Dormant Projects, H1 2015 72
Septic Shock - Discontinued Products, H1 2015 73
List of Figures
Number of Products under Development for Septic Shock, H1 2015 10
Number of Products under Development for Septic Shock - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Top 10 Targets, H1 2015 33
Number of Products by Stage and Top 10 Targets, H1 2015 34
Number of Products by Top 10 Mechanism of Actions, H1 2015 35
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 36
Number of Products by Top 10 Routes of Administration, H1 2015 37
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38
Number of Products by Top 10 Molecule Types, H1 2015 39
Number of Products by Stage and Top 10 Molecule Types, H1 2015 40
Explore more reports on Infectious Diseases Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnRMarketResearch.com/, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article